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BACKGROUND AND PURPOSE
Transient receptor potential ankyrin-1 (TRPA1) activation is known to mediate neurogenic vasodilatation. We investigated the
mechanisms involved in TRPA1-mediated peripheral vasodilatation in vivo using the TRPA1 agonist cinnamaldehyde.
EXPERIMENTAL APPROACH
Changes in vascular ear blood ﬂow were measured in anaesthetized mice using laser Doppler ﬂowmetry.
KEY RESULTS
Topical application of cinnamaldehyde to the mouse ear caused a signiﬁcant increase in blood ﬂow in the skin of anaesthetized
wild-type (WT) mice but not in TRPA1 knockout (KO) mice. Cinnamaldehyde-induced vasodilatation was inhibited by the phar-
macological blockade of the potent microvascular vasodilator neuropeptide CGRP and neuronal NOS-derived NO pathways.
Cinnamaldehyde-mediated vasodilatation was signiﬁcantly reduced by treatment with reactive oxygen nitrogen species (RONS)
scavenger such as catalase and the SOD mimetic TEMPOL, supporting a role of RONS in the downstream vasodilator TRPA1-
mediated response. Co-treatment with a non-selective NOS inhibitor L-NAME and antioxidant apocynin further inhibited the
TRPA1-mediated vasodilatation. Cinnamaldehyde treatment induced the generation of peroxynitrite that was blocked by the
peroxynitrite scavenger FeTPPS and shown to be dependent on TRPA1, as reﬂected by an increase in protein tyrosine nitration in
the skin of WT, but not in TRPA1 KO mice.
CONCLUSION AND IMPLICATIONS
This study provides in vivo evidence that TRPA1-induced vasodilatation mediated by cinnamaldehyde requires neuronal NOS-
derived NO, in addition to the traditional neuropeptide component. A novel role of peroxynitrite is revealed, which is generated
downstream of TRPA1 activation by cinnamaldehyde. This mechanistic pathway underlying TRPA1-mediated vasodilatation may
be important in understanding the role of TRPA1 in pathophysiological situations.
Abbreviations
AITC, allyl isothiocyanate; eNOS, endothelial NOS; H2O2, hydrogen peroxide; iNOS, inducible NOS; nNOS, neuronal NOS;
NK, neurokin; NO2
, nitrite; NO3
, nitrate; RONS, reactive oxygen nitrogen species; TRPA1, transient receptor potential
ankyrin-1; TRPV1, transient receptor potential vanilloid-1
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Introduction
Primary sensory neurons are widely distributed in the central
and peripheral nervous system, and have a physiological role
in maintaining vascular homeostasis (Russell et al., 2014), al-
though their exact pathophysiological relevance is unclear.
Sensory nerve stimulation leads to the release of neuropep-
tides such as CGRP and substance P, which are established
neurogenic-dependent vasodilators (Brain et al., 1985;
Lembeck et al., 1992). CGRP, in addition to its potent micro-
vascular vasodilator activity, possesses protective mecha-
nisms, which are potentially important for physiological
and pathological conditions in the cardiovascular system
(Russell et al., 2014). We are yet to fully understand themech-
anisms involved in the activation of the nerves. The discov-
ery of transient receptor potential ankyrin-1 (TRPA1), which
is located in 60–75% of transient receptor potentials
vanilloid-1 (TRPV1) expressing C- and Aδ-sensory ﬁbres
(Story et al., 2003; Kobayashi et al., 2005) has dramatically in-
creased our understanding of the mechanism underlying ac-
tivation of the sensory neurons and release of neuropeptides
(Bautista et al., 2005). Indeed, TRPA1 is expressed on rat sen-
sory nerves (Bautista et al., 2005) and human skin (Atoyan
et al., 2009). It is activated by various exogenous agonists, in-
cluding pungent extracts such as allyl isothiocyanate (AITC)
from mustard oil, cinnamaldehyde from cinnamon and alli-
cin from garlic, which all modify cysteine and lysine residues
on the N-terminus of the TRPA1 channel (Bandell et al., 2004;
Bautista et al., 2005; Hinman et al., 2006). Other activators in-
clude noxious cold temperature (Story et al., 2003; Aubdool
et al., 2014), products of oxidative stress, lipid peroxidation
and hydrogen sulphide (Trevisani et al., 2007; Andersson
et al., 2008; Graepel et al., 2011; Eberhardt et al., 2014).
The role of TRPA1 in inﬂuencing the cardiovascular sys-
tem is less understood. Deletion of the TRPA1 gene had no ef-
fect on blood pressure and cardiac function either under
baseline conditions or in response to angiotensin-II in mice
(Bodkin et al., 2014). However, systemic administration of
the highly selective TRPA1 agonist cinnamaldehyde induced
a transient hypotensive response in wild-type (WT) mice but
not in TRPA1 knockout (KO) mice (Pozsgai et al., 2010), sug-
gesting that TRPA1 may be involved in regulating the
autonomic vasovagal response. Nevertheless, more studies
have focused on the role of TRPA1 in regulating the periph-
eral vascular tone. Whilst the neuronal expression and func-
tion of TRPA1 is established, less is known about its vascular
expression. TRPA1 is found on the endothelium of cerebral
arteries, but not in other vascular beds of rats and humans
(Sullivan et al., 2015), and AITC mediates an endothelium-
dependent relaxation by activating TRPA1 in rat cerebral ar-
teries (Earley et al., 2009). Topical application of mustard oil
mediates vasodilatation in the ear skin in a CGRP-dependent
manner (Grant et al., 2005; Pozsgai et al., 2010), while
cinnamaldehyde causes a TRPA1-dependent vasodilatation
in the hindpaw in vivo (Pozsgai et al., 2010). Recently, we
demonstrated that TRPA1 activation by local cold exposure
in the hindpaw vasculature induces a transient vasoconstric-
tion followed by vasodilatation, which is essential in
returning blood ﬂow to baseline and protecting against local
cold-induced injuries (Aubdool et al., 2014). The cold-
induced vasodilator restorative response was mediated by
sensory nerve-derived dilator neuropeptides and NO. This
study points to an important role of TRPA1 in regulating pe-
ripheral blood ﬂow and a potential target for novel therapeu-
tic approaches (Aubdool et al., 2014). However, the critical
mechanisms involved in the vasodilator response following
TRPA1 activation are unknown.
In the present study, we investigate the mechanisms in-
volved in TRPA1-mediated vasodilatation using the selective
TRPA1 agonist cinnamaldehyde in the mouse ear model
in vivoby laserDopplerﬂowmetry. A pharmacogenetic approach
allowed us to examine the relative contribution of CGRP and
neuronal NOS (nNOS)-derived NO in cinnamaldehyde-induced
neurogenic vasodilatation. Novel evidence is provided to reveal
the pivotal role of reactive oxygen nitrogen species (RONS),
especially peroxynitrite generation downstream of TRPA1 acti-
vation, with results that highlight a critical role for RONS
inﬂuencing the neurogenic vasodilatation.
Methods
In vivo experiments were performed according to the UK
Home Ofﬁce Animals (Scientiﬁc Procedure) Act 1986 and
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King’s College London Animal Care and Ethics Committee.
Animal studies are reported in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015).
Male mice were fed ad libitum a normal diet and water in a
climatically-controlled environment (22 ± 2°C), maintained
under ﬁltered positive pressure ventilation on a 12–12 h
dark:light cycle, beginning at 07:00 h. CD1 mice (20–30 g,
8–12 weeks of age, #022, Charles River, UK) and genetically
altered mice (8–12 weeks of age) were used, including
TRPA1 KO (Kwan et al., 2006) (C57BL/6-B6129P1/F2J mixed
genetic background), and WT littermates were bred from
heterozygotic mice, which were kindly provided by Drs
Kelvin Kwan (Harvard Medical School, Boston, MA, USA)
and David Corey (Harvard Medical School, Boston, MA,
USA). TRPV1 KO (Caterina et al., 2000) and α-CGRP KO mice
(Salmon et al., 1999) were raised on a C57/BL6 background,
and their WT littermates were used as controls. Up to ﬁve
mice were housed initially to a cage and then less as they
were used for experiments from a minimum of 5 days after
delivery to the animal unit. The mouse cages (U-TEMP
Polyetherimide, Techniplast, UK) were 820 cm2 by 15.5 cm
depth. Bedding was supplied from EcoPure (Nestpak’s
Aspenchips). All experiments were conducted in a blinded
manner, and mice were randomly allocated to treatment
groups. The experimenter was blinded towards treatment or
genetic background at the time of the experiment. The num-
ber of mice used in each group is indicated in the respective
ﬁgure legends. Mice were anaesthetized i.p. with ketamine
(75 mg·kg1) and medetomidine (1 mg·kg1) throughout
the experiment (Aubdool et al., 2014). At the end of the
experiment, all mice were killed by cervical dislocation.
Measurement of vasoactive responses in vivo
Following anaesthesia, cutaneous blood ﬂow was assessed
concomitantly in both ears by laser Doppler ﬂowmeter (Moor
Instruments Ltd, UK) connected to a PowerLab data acquisi-
tion system (AD instruments, UK) whereby a probe, allowing
blood ﬂow to be measured precisely at one point in the ear
(1 mm2 and to 1–2 mm depth) was placed directly over the
skin surface (Grant et al., 2002; 2005). The probe was ﬁxed
in position over the skin with a normal laboratory manipula-
tor by clamping onto a black acetal shank. Following baseline
recording for 5 min, 20 μL of cinnamaldehyde (10%) was top-
ically applied to the ipsilateral ear and 20 μL of vehicle (10%
DMSO in ethanol) on the contralateral ear. Blood ﬂow was
subsequently measured for 30 min. Blood ﬂow data were col-
lected as ﬂux units that are proportional to blood ﬂow and
expressed as area under the recorded ﬂux versus time trace
for the entire recording period following topical treatment
(×103 ﬂux units). This model was ﬁrst developed by Grant
et al. (2002), and the simultaneous measurement of blood
ﬂow allows each mouse to serve as its own control, reducing
animal use (Grant et al., 2002; 2005; Starr et al., 2008;
Aubdool et al., 2014).
In some experiments, a full-ﬁeld perfusion imager (FLPI,
Moor Instruments Ltd) was also used under a similar set-up
to assess blood ﬂow on the whole ear skin (Starr et al., 2008;
Pozsgai et al., 2010; Aubdool et al., 2014). The FLPI works on
the same principle as the laser Doppler ﬂowmeter’s probe,
except that it uses laser speckle imaging to produce high-
resolution imaging of real-time assessment of skin blood ﬂow
prior to and following treatment, at regular 1 min intervals.
Comparison studies examining the similarities and differ-
ences between both techniques have shown that there is a
high correlation (R2 = 0.98) in cerebral blood ﬂow measure-
ments in adjacent areas (Dunn et al., 2001). Blood ﬂow traces
were created by the image processing software MoorFLPI
measurement V3.0 (Moor Instruments Ltd) at regular inter-
vals of 4 s and analysed similarly to experiments using the la-
ser Doppler ﬂowmeter.
Measurement of nitrite formation using the
Griess assay
Nitrite (NO2
)/nitrate (NO3
) content was assessed by the
Griess assay in vehicle- and cinnamaldehyde-treated ear skin
tissues at 30 min following treatment. Skin tissues were ho-
mogenized in acetonitrile, and homogenates were then cen-
trifuged (8000 g, 4°C, 10 min) and supernatant was
collected. NO3
 content was reduced to NO2
 by incubating
80 μL of sample with 20 μL of 1 U·mL1 nitrate reductase
and 10 μL of 1 mM NADPH for 30 min at 37°C (Fernandes
et al., 2012). This was followed by the addition of 100 μL of
Griess reagent (5% H3PO4 containing 1% sulfanilic acid and
0.1% N-1-napthylethylenediamine) (Fluka, Switzerland) and
further incubated for another 30 min at 37°C. Absorbance
was read at 550 nm using a spectrophotometer (SpectraMax
190, Molecular Devices Corporation, CA, USA). The absor-
bance of each sample was, after subtracting the background
reading, compared against a standard curve (0–300 μM
sodium nitrite) and expressed as NOx levels mg1 of tissue
protein. All reagents were purchased from Sigma (UK).
Superoxide measurements using the Lucigenin
assay
Superoxide release was measured by chemiluminescence
using bis-N-methylacridinium nitrate (Lucigenin, Sigma), as
previously described (Fernandes et al., 2013; Aubdool et al.,
2014). Following 30 min of topical treatment, vehicle- and
cinnamaldehyde-treated ear skin tissues were prepared, as de-
scribed previously (Fernandes et al., 2013; Aubdool et al.,
2014). The samples were placed in 100 μL of modiﬁed Krebs’
buffer (composition of 131 mM NaCl, 5.6 mM KCl, 25 mM
NaHCO3, 1 mM NaH2PO4·H2O, 5 mM glucose, 5 mM HEPES,
100 μM L-arginine, 2.5 mM CaCl2, 1 mM MgCl2 and 100 μM
NADPH, pH 7.4), and a further 100 μL of modiﬁed Krebs’
buffer containing Lucigenin (10 mM) and NADPH (500 μM)
was added to each sample with or without SOD (50 U·mL1).
Chemiluminescence was measured after 5 min using a
GloMax 20/20 luminometer (Promega, UK). Results are
expressed as the difference in the relative light units mg1
of protein in the presence and absence of SOD after subtrac-
tion of background luminescence (Fernandes et al., 2013).
All reagents were purchased from Sigma.
Preparation of lysates and western blotting
Mice ear skin tissues were collected 30 min post-treatment of
vehicle and cinnamaldehyde, and snap frozen at 80°C until
processing. Tissue was then lysed in SDS lysis buffer
containing protease (1 tablet per 50mL, Roche) and phospha-
tase (1 tablet per mL, Roche) inhibitor. Lysates were clariﬁed
by centrifuging at 2600 g for 10 min at 4°C. Protein
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concentration was assessed using the Bradford dye-binding
method kit (Bio-Rad). Fifty micrograms of protein was loaded
and separated by SDS-PAGE and transferred to PVDF mem-
branes using a semi-dry technique (Aubdool et al., 2014).
Membranes were blocked with 5% milk in PBS containing
0.1% Tween and incubated with primary antibodies against
nitrotyrosine (1:500 dilution, Abcam ab61392) (Smillie
et al., 2014) and loading control β-actin (1:2000, Sigma
A1978) dilution in 3% BSA in PBS and 0.1% Tween for 16 h
at 4°C. Membranes were washed further with PBS 0.1%
Tween and incubated with a horseradish peroxidase conju-
gated anti-mouse secondary antibody (1:2000/5000 dilution,
Sigma). Proteins were detected by enhanced chemilumines-
cence (Piercenet, UK) and densitometric analysis performed
using Image J analysis software (NIH, USA). Total
nitrotyrosine signal was calculated and normalized to the
loading control β-actin.
Data analysis
We have adhered to the study design and analysis guidelines
for British Journal of Pharmacology (Curtis et al. 2015). All
data are presented as mean ± SEM. Most experiments in this
study involved four groups and hence, a power analysis for
a two-way ANOVA design was used, based on previously pub-
lished data from themouse earmodel (Grant et al., 2002; Starr
et al., 2008; Pozsgai et al., 2010; Graepel et al., 2011; Aubdool
et al., 2014). Sample size in this study varied between n = 4–7
(independent values per experiment). Statistical analysis was
performed using GraphPad Prism (Version 5.0) software. Data
statistical analysis was performed using Student’s two-tailed
paired t-test or two-way ANOVA followed by Bonferroni’s
comparison post hoc test. Only a sample size ≥5 was subjected
to statistical analysis as per the journal’s guidelines. P < 0.05
represented a signiﬁcant difference between groups.
Materials
All drugs were purchased from Sigma unless otherwise stated.
HC030031 (Tocris, UK) was dissolved in 10% DMSO in saline
and administered i.p. at 100 mg·kg1 (McNamara et al., 2007;
Aubdool et al., 2014). Ruthenium red was dissolved in saline
and administered i.p. at 3 mg·kg1 (Cordova et al., 2011).
CGRP8–37 was dissolved in 0.01% BSA and administered i.v.
at 400 nmol·kg1 (Tocris) (Grant et al., 2002; Aubdool et al.,
2014). SR140333 (a gift from Dr X. Emonds-Alt, Sanoﬁ, Tou-
louse, France) was dissolved in saline and administered i.v.
at 480 nmol·kg1 (Starr et al., 2008; Aubdool et al., 2014).
Glibenclamide was used i.v. at 20mg·kg1 (Buckingham et al.,
1989). L-NAME, SMTC or 1400 W was administered i.v. at
15mg·kg1 (Starr et al., 2008; Aubdool et al., 2014), 10-
mg·kg1 (Gozal et al., 1996; Aubdool et al., 2014) and 3-
mg·kg1 (Raimura et al., 2013) respectively. SMTC is 10-fold
more potent against nNOS than endothelial NOS (eNOS)
(Furﬁne et al., 1994) and 1400 W is >50-fold more potent
against inducible NOS (iNOS) than eNOS (Garvey et al.,
1997). Indomethacin was dissolved in 5% NaHCO3 in saline
and administered i.v. at 20mg·kg1 and s.c. at 5mg·kg1 (Starr
et al., 2008). N-acetylcysteine and TEMPOL (Tocris) were admin-
istered i.p. at 300mg·kg1 (Zwingmann and Bilodeau, 2006) and
i.v. at 30 mg·kg1 (Starr et al., 2008; Aubdool et al., 2014) respec-
tively. Catalase or its denatured form was administered i.p. at
25000 U·kg1 (Starr et al., 2008). Deferoxamine and apocynin
were administered at 25 mg·kg1 i.p. and 20 mg·kg1 i.v. (Starr
et al., 2008) respectively. 5,10,15,20-Tetrakis(4-sulfonatophenyl)
porphyrinato iron (III), chloride (FeTPPS) or the iron-free form
of FeTPPS (TPPS, negative control) (Santa Cruz Biotechnology,
Germany) were administered i.v. at a dose of 30 mg·kg1
(Salvemini et al., 1998). These drugs were administered i.v.
5min, i.p. 30min and s.c. 60min before baselinemeasurements.
The doses used were chosen based on previous and preliminary
studies.
Results
Cinnamaldehyde-induced vasodilatation is
dependent on TRPA1
Topical application of cinnamaldehyde (1–30%) caused an
increase in blood ﬂow following treatment compared with
vehicle-treated ears in WT mice, which lasted for 30 min
and returned to baseline by 60 min (Figure 1A and B;
Supporting Information Fig. S1 and S2), as determined by la-
ser Doppler ﬂowmetry. The dose of 10% cinnamaldehyde was
chosen for the subsequent studies as this dose mediates an
axon reﬂex ﬂare reaction on the forearm of healthy subjects,
with an increase in blood ﬂow (Namer et al., 2005), and here,
it evoked a signiﬁcant reproducible increase in skin blood
ﬂow (Supporting Information Fig. S1).
To determine the role of TRP channels in
cinnamaldehyde-induced vasodilatation, WT mice were pre-
treated with the non-selective cation channel blocker ruthe-
nium red (3 mg·kg1) (Cordova et al., 2011), and a signiﬁcant
decrease in cinnamaldehyde-induced vasodilatation was ob-
served compared with control groups (Supporting Informa-
tion Fig. S3). More speciﬁcally, the involvement of TRPA1
was investigated using the selective TRPA1 antagonist
HC030031 (100 mg·kg1) (McNamara et al., 2007; Aubdool
et al., 2014) in WT mice. Figure 1C shows that
cinnamaldehyde-induced vasodilatation was abolished in
HC030031 pre-treated WT mice compared with control,
supporting our previous ﬁnding (Aubdool et al., 2014). The
role of TRPA1 is conﬁrmed as cinnamaldehyde-induced vaso-
dilatation was absent in TRPA1 KO mice (Figure 1D and E).
As TRPA1 is co-expressed in 60–75% of TRPV1-expressing
sensory neurons (Story et al., 2003; Kobayashi et al., 2005), we
determined the selectivity of cinnamaldehyde by examining
its effects on TRPV1 using WT and TRPV1 KO mice. The ge-
netic deletion of TRPV1 had no signiﬁcant effect on
cinnamaldehyde-induced vasodilatation (Figure 1F).
Cinnamaldehyde-induced vasodilatation is
dependent on sensory neuropeptide CGRP
The role of the two major vasodilator neuropeptides CGRP
and substance P was investigated in cinnamaldehyde-
induced vasodilatation. Pre-treatment with both neuropep-
tide receptor antagonists mixed together caused a signiﬁcant
decrease in cinnamaldehyde-induced vasodilatation in WT
mice (Figure 2A). Whilst pre-treatment with SR140333 alone
had no signiﬁcant effect on this response (Figure 2B), WT
mice pre-treated with CGRP8–37 alone abolished
cinnamaldehyde-induced increase in blood ﬂow responses
(Figure 2C), indicating the major role of CGRP. In a
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complementary manner, a similar response was observed in
α-CGRPWT and KOmice (Figure 2D). Because CGRP-induced
vasodilatation is dependent on the activation of KATP chan-
nels, we investigated the effects of the KATP channel blocker
glibenclamide (Buckingham et al., 1989). Pre-treatment with
glibenclamide caused a signiﬁcant reduction in vasodilata-
tion, supporting the importance of KATP channels in mediat-
ing this response (Figure 2E).
Figure 1
Cinnamaldehyde (CA)-induced vasodilatation is dependent on TRPA1. Blood ﬂowwasmeasured in response to topical cinnamaldehyde (10% CA)
and vehicle (10% DMSO in ethanol) in the anaesthetized mouse ear. Results recorded over 30 min and analysed as AUC. (A) Representative blood
ﬂow trace of CA-induced response in WT mouse. Dotted lines represent topical administration of CA or vehicle. (B) Representative blood ﬂow re-
sponse as observed in pseudo-colour images alongside grey/black image by laser speckle imager at baseline, 5-30 min following treatment in WT
mouse. (C) Group mean data for CA-induced vasodilatation in WT mice pretreated with the TRPA1 antagonist HC030031 (100 mg·kg1, n = 5) or
control (10% DMSO in saline, n = 6). (D) Group mean data for CA-induced vasodilatation in TRPA1 WT and KO mice (n = 5). (E) Representative
blood ﬂow response as observed in pseudo-colour images by laser speckle imager at baseline and 30min following treatment in TRPA1WT and KO
mouse. (F) Group mean data for CA-induced vasodilatation in WT and TRPV1 KO mice (n = 5). All errors indicate SEM. *P < 0.05 versus vehicle-
treated ears of WT mice; #P < 0.05 versus CA-treated ears of WT mice (2-way ANOVA and Bonferroni post hoc test).
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Figure 2
Cinnamaldehyde (CA)-induced vasodilatation is dependent on CGRP. Blood ﬂow was measured in response to topical cinnamaldehyde (10% CA)
and vehicle (10% DMSO in ethanol) in the anaesthetized mouse ear. Results recorded over 30min and analysed as AUC. Group mean data for
CA-induced vasodilatation in WT mice pretreated with (A) a combination of CGRP receptor antagonist CGRP8-37 (400 nmol•kg
1) and substance
P NK1 receptor antagonist SR140333 (480 nmol•kg1, n = 5) or control (0.01% BSA in saline, n = 5), (B) SR140333 alone or control (saline, n = 5)
and (C) CGRP8-37 alone or control (0.01% BSA in saline, n = 5). (D) CA-induced vasodilatation in α-CGRP WT and KO mice (n = 5). Effects of
pretreatment of (E) ATP-sensitive K+ channels (KATP) blocker glibenclamide (20 mg•kg1, n = 5). All errors indicate SEM. *P < 0.05 versus
vehicle-treated ears of WT mice; #P < 0.05 versus CA-treated ears of WT mice (2-way ANOVA and Bonferroni post hoc test).
BJP A A Aubdool et al.
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nNOS-derived NO and neuropeptides are
involved in cinnamaldehyde-induced
vasodilatation
We subsequently investigated the role of other classical
vasodilators such as prostaglandins and NO. WT mice
pretreated with the cyclooxygenase inhibitor indomethacin
(20 mg·kg1) (Starr et al., 2008) showed no signiﬁcant
changes on cinnamaldehyde-induced neurogenic vasodilata-
tion (Supporting Information Fig. S3).
We next examined the formation of NO by assessing ni-
trite levels using the Griess assay. Ear tissues treated with
cinnamaldehyde for 30 min showed an increase in NO
formation compared with vehicle-treated tissues (Figure 3A).
Pre-treatment with the non-selective NOS inhibitor L-NAME
(15 mg·kg1) (Starr et al., 2008) caused a signiﬁcant reduction
in cinnamaldehyde-induced increase in blood ﬂow compared
with control (Figure 3B), but without signiﬁcant effect on
vehicle-treated ear blood ﬂow. Moreover, co-treatment with
L-NAME, CGRP8–37 and SR140333 (Aubdool et al., 2014)
abolished the cinnamaldehyde-induced vasodilatation, com-
parable with the control group (Figure 3C and Table 1).
To determine the source of NO, we used iNOS-speciﬁc and
nNOS-speciﬁc inhibitors. Whilst the selective iNOS inhibitor
1400W (3mg·kg1) (Raimura et al., 2013) with or without the
neuropeptide receptor antagonists had no further signiﬁcant
reduction in blood ﬂow (Supporting Information Fig. S4), the
nNOS inhibitor (SMTC) (Gozal et al., 1996; Aubdool et al.,
2014) inhibited this response (Figure 3B), and co-treatment
Figure 3
Cinnamaldehyde (CA)-induced vasodilatation is dependent on nNOS-derived NO. Blood ﬂow was measured in response to topical
cinnamaldehyde (10% CA) and vehicle (10% DMSO in ethanol) in the anaesthetized mouse ear. Results recorded over 30 min and analysed as
AUC. (A) Nitrite (NO2
)/nitrate (NO3
) levels as shown indicating NO formation (NOx) using Griess assay in ear tissues of WT mice treated with
vehicle or 10% CA for 30 min (n = 5). (B) Group mean data for CA-induced vasodilatation in WT mice pretreated with the non-selective NOS
inhibitor L-NAME (15 mg•kg1, n = 6), nNOS inhibitor SMTC (10 mg•kg1, n = 7) or control (saline, n = 6) alone. (C) Group mean data for
CA-induced vasodilatation in WT mice pretreated with control (saline, n = 5), a combination of CGRP8-37 (400 nmol•kg
1) and SR140333 (480
nmol•kg1) alone (n = 5) or with L-NAME (n = 5) or SMTC (n = 6). All errors indicate SEM. *P < 0.05 versus vehicle-treated ears of WT mice;
#P < 0.05 versus CA-treated ears of WT mice (2-way ANOVA, Bonferroni post hoc test or Student’s two-tailed t-test).
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with neuropeptide receptor antagonists further attenuated
this response (Figure 3C). These results highlight the major
role of nNOS in cinnamaldehyde-induced vasodilatation.
A role for superoxide and peroxynitrite in
cinnamaldehyde-induced vasodilatation
ROS are involved in modulating neurogenic-induced vasodi-
latation following sensory neuron activation by capsaicin in
the mouse ear (Starr et al., 2008). Pre-treatment with the anti-
oxidant N-acetylcysteine (300 mg·kg1) (Zwingmann and
Bilodeau, 2006) or apocynin (acting as a ROS scavenger at 20-
mg·kg1) (Heumuller et al., 2008) caused a signiﬁcant de-
crease in cinnamaldehyde-induced vasodilatation compared
with control group (Figure 4A and B). To investigate the role
of hydrogen peroxide (H2O2), the H2O2 scavenger catalase
(25000 U·kg1) (Starr et al., 2008) was used. Pre-treatment with
catalase had no effect on cinnamaldehyde-induced responses
comparedwithWTmice treatedwith thedeactivated enzyme cat-
alase (control, Figure 4C). Using the membrane permeable SOD
mimetic TEMPOL (30mg·kg1) (Starret al., 2008),we observed re-
duced vasodilator response compared with control group in WT
mice (Figure 4D). Treatment with cinnamaldehyde resulted in re-
duced superoxide level in the ear tissue samples, suggesting that
superoxide may react with another mediator (possibly with the
increase in NO; Figure 3A) forming a product, which contributes
to cinnamaldehyde-induced vasodilatation (Figure 4E). As co-
treatment using a NOS inhibitor (L-NAME) and antioxidant
apocynin showed reduction in cinnamaldehyde-induced vasodi-
latation, it is possible that superoxide reacts with NO to produce
RONS such as peroxynitrite (Figure 4F).
To further investigate the role of peroxynitrite, the iron
chelator and peroxynitrite scavenger deferoxamine (25-
mg·kg1) (Beckman et al., 1990) or the selective peroxynitrite
scavenger FeTPPS (30 mg·kg1) was administered in WT mice
and caused a signiﬁcant reduction in cinnamaldehyde-
induced vasodilatation (Figure 5A and B). There was no
change in responses in WT mice pre-treated with the iron-
free form of FeTPPS, TPPS (negative control; Supporting In-
formation Fig. S5). The efﬁcacy of FeTPPS to scavenge
peroxynitrite was further conﬁrmed by western blotting to
detect protein tyrosine nitration using an antibody against
nitrotyrosine residues (Figure 5C and D and Supporting Infor-
mation Fig. S6). Cinnamaldehyde induced an increase in
nitrosylated proteins, which was signiﬁcantly reduced in
WT mice pre-treated with FeTPPS (Figure 5C) and in TRPA1
KO mice (Figure 5D), suggesting a potential role for
peroxynitrite downstream of cinnamaldehyde activation of
TRPA1 in mediating the observed vasodilatation.
Discussion
This study shows that TRPA1 stimulation by cinnamaldehyde
can mediate neurogenic vasodilatation in the peripheral
vasculature mediated to a large extent by the sensory neuro-
peptide CGRP. Cinnamaldehyde-induced neurogenic vasodi-
latation was (i) absent in TRPA1 KO mice, (ii) blocked by co-
treatment with NOS inhibitor and antioxidant and (iii)
resulted in increased protein tyrosine nitration, which was
inhibited by the peroxynitrite scavenger FeTPPS and absent
in TRPA1 KO mice, implying that RONS production is an es-
sential component of TRPA1-mediated neurogenic vasodila-
tation. We show for the ﬁrst time that independent of
TRPV1, RONS are involved in cinnamaldehyde-mediated va-
sodilatation, possibly generated through a reaction between
NO and superoxide downstream of TRPA1 activation.
Studies investigating the mechanisms underlying TRPA1
activation have relied on selective agonists, and to date,
cinnamaldehyde has proven to be among the most selective
chemical agonist of TRPA1 in vitro (Bodkin and Brain, 2011).
Cinnamaldehyde excites a subset of sensory neurons highly
enriched in cold-sensitive neurons in vitro (Bandell et al.,
2004), and at a dose of 10%, it mediates an axon reﬂex ﬂare
reaction on the forearm of healthy subjects (Namer et al.,
2005). However, it remains unknown whether this response
is TRPA1-dependent in humans. Following our previous
evidence that cinnamaldehyde increases blood ﬂow in the
hindpaw vasculature and inﬂuences changes in blood pres-
sure in vivo via TRPA1 activation (Pozsgai et al., 2010),weprovide
Table 1
Effects of neuropeptide receptor antagonists and NOS inhibitors on cinnamaldehyde-induced vasodilatation
Treatment n Vehicle (20 μL) CA (10%)
Control 6 55.7 ± 7.4 304.4 ± 28.1*
L-NAME 5 33.2 ± 7.2 203.5± 44.6*,#
SMTC 6 44.6 ± 5.1 83.2 ± 27.9*,#
Control 5 52.8 ± 8.6 228.9 ± 16.3*
CGRP8–37 + SR140333 5 39.4 ± 3.1 101.5 ± 17.8
*,#
CGRP8–37 + SR140333 + L-NAME 5 46.7 ± 6.1 68.1 ± 13.3
#
CGRP8–37 + SR140333 + SMTC 6 44.6 ± 5.1 83.2 ± 27.9
#
Blood ﬂow was measured in response to topical cinnamaldehyde (10% CA) and vehicle (10% DMSO in ethanol) in the anaesthetized mouse ear. Results
were recorded over 30 min and analysed as AUC. WT mice were pre-treated with the non-selective NOS inhibitor L-NAME (15 mg·kg1, n = 6), nNOS
inhibitor SMTC (10 mg·kg1, n = 7) or control (saline, n = 6) with and without CGRP8–37 (400 nmol·kg
1) and SR140333 (480 nmol·kg1) (n = 5–6). All
errors indicate SEM.
*P < 0.05 versus vehicle-treated ears of WT mice.
#P < 0.05 versus CA-treated ears of WT mice (2-way ANOVA and Bonferroni post hoc test).
BJP A A Aubdool et al.
2426 British Journal of Pharmacology (2016) 173 2419–2433
Figure 4
A role for ROS in mediating cinnamaldehyde (CA)-induced vasodilatation. Blood ﬂow was measured in response to topical cinnamaldehyde (10%
CA) and vehicle (10%DMSO in ethanol) in the anaesthetized mouse ear. Results recorded over 30 min and analysed as AUC. Groupmean data for
CA-induced vasodilatation in WT mice pretreated with the (A) ROS scavenger N-acetylcysteine (300 mg•kg1, n = 6) or control (saline, n = 6), (B)
apocynin (20 mg•kg1, n = 7) or control (saline, n = 6), (C) H2O2 scavenger catalase (n = 4) or control (denatured catalase enzyme, n = 4) and (D)
SOD mimetic TEMPOL (30 mg•kg1, n = 5) or control (saline, n = 5). (E) Superoxide levels in vehicle-treated or CA-treated ears of WT mice at
30 min following treatment, as measured by Lucigenin assay (n = 5). (F) Group mean data for CA-induced vasodilatation in WT mice pre-treated
L-NAME and apocynin or control (saline, n = 6). Data represent mean ± SEM. *P < 0.05 versus vehicle-treated ears of WT mice; #P < 0.05 versus
CA-treated ears of WT mice (2-way ANOVA, Bonferroni post hoc test or Student’s two-tailed t-test).
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evidence of its vasodilator effects in the mouse ear vasculature,
in a TRPA1-dependent manner. Despite suggestions of possible
interactions between TRPA1 and TRPV1 on sensory neurons
(Kobayashi et al., 2005), cinnamaldehyde-induced vasodilata-
tion was not affected by TRPV1 gene deletion. We also
demonstrated that the pharmacological blockade of transient
receptor potential melastatin-8 using AMTB did not affect
this response (Aubdool et al., 2014). These combined results
imply that TRPA1 activation can act alone to mediate
cinnamaldehyde-evoked vasodilatation in the skin.
Figure 5
Peroxynitrite (ONOO) is involved in cinnamaldehyde (CA)-induced vasodilatation. Blood ﬂow was measured in response to topical
cinnamaldehyde (10% CA) and vehicle (10% DMSO in ethanol) in the anaesthetized mouse ear. Results recorded over 30 min and analysed as
AUC. Group mean data for CA-induced vasodilatation in WT mice pretreated with (A) deferoxamine (25 mg•kg1, n = 6) or control (saline,
n = 6) or (B) the peroxynitrite scavenger FeTPPs (30 mg•kg1, n = 5) or control (n = 5). (C) Representative western blot (top panel) and densito-
metric analysis (bottom panel, n = 5) of nitrotyrosine protein expression, as a marker of peroxynitrite formation and β-actin (loading control) in
vehicle-treated and CA-treated ear tissues of WT mice pretreated with FeTPPs or control at 30 min following treatment (left panel). (D) Represen-
tative western blot (top panel) and densitometric analysis (bottom panel, n = 5) of nitrotyrosine protein expression and β-actin (loading control) in
vehicle-treated and CA-treated ear tissues of TRPA1 WT and KOmice at 30 min following treatment (left panel). Data represent mean ± SEM. *P<
0.05 versus vehicle-treated ears of WT mice; #P < 0.05 versus CA-treated ears of WT mice (2-way ANOVA and Bonferroni post hoc test).
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TRPA1-dependent vasodilatation has been previously
shown to be mediated by sensory neuropeptides (Grant
et al., 2005; Pozsgai et al., 2010; Graepel et al., 2011; Aubdool
et al., 2014). Pharmacological blockade of the neurokinin-1
(NK1) receptor using SR140333 alone, at doses previously
shown to inhibit substance P-induced vasodilatation (Grant
et al., 2002; Starr et al., 2008) did not affect TRPA1-induced re-
sponses, suggesting that substance P is not primarily involved
in this response, despite its established co-localization with
CGRP in sensory nerves. We have previously shown that
both capsaicin- and mustard oil-induced vasodilatation are
not reduced in NK1 receptor knockout mice but blocked
when these KO mice are pre-treated with the CGRP receptor
antagonist (Grant et al., 2002, 2005). This suggests that the
NK1 receptor antagonist is only able to reduce vasodilatation
once the CGRP receptor component has been removed.
Although α-CGRP is a potent microvascular vasodilator in
the cutaneous, coronary and cerebral vasculature, CGRP
receptor antagonists do not affect baseline cardiovascular
parameters in humans (Olesen et al., 2004) or rodents (Escott
and Brain, 1993; Russell et al., 2014). Here, cinnamaldehyde-
induced vasodilatation was inhibited when the α-CGRP gene
was deleted or its receptors were blocked, consistent with pre-
vious ﬁndings using other TRPA1 activators in the vascula-
ture (Pozsgai et al., 2012; Aubdool et al., 2014; Eberhardt
et al., 2014). CGRP binds to its receptor complex and can
mediate its vasodilator effects in a cAMP-dependent pathway,
mediating the opening of KATP-sensitive K
+ channels (Nelson
et al., 1990) (Figure 6). Indeed, pre-treatment with
glibenclamide signiﬁcantly reduced cinnamaldehyde-
induced vasodilatation, suggesting that cinnamaldehyde
may activate TRPA1 and release CGRP from sensory neurons,
which further mediates vasodilatation by opening KATP chan-
nels on the vascular smooth muscle cells (Figure 6).
An interesting ﬁnding in this study was that whilst
CGRP8–37 and not SR140333 was able to inhibit
cinnamaldehyde-induced vasodilatation, the simultaneous
pharmacological blockade of both the CGRP and substance
P NK1 receptors substantially reduced cinnamaldehyde-
induced vasodilatation. However, a small but signiﬁcant
vasodilatation remained, and this suggests a possible interac-
tion between these neuropeptides, which have previously
Figure 6
Schematic diagram of TRPA1-induced vasodilatation involving CGRP, NO and peroxynitrite. Cinnamaldehyde activates TRPA1 on sensory neuron
to mediate increase in [Ca2+], leading to the release of the neuropeptide CGRP and nNOS-derived NO. CGRP acts on the CGRP receptor complex
to increase cAMP, further phosphorylating PKA and opening KATP channels, mediating relaxation. NO acts on stimulating sGC to subsequently
form cGMP, activating PKG, which causes reuptake of Ca2+ and opens K+ channels, leading to hyperpolarization of the membrane and further
relaxing the VSMC. RONS, such as superoxide possibly being produced following TRPA1 activation, can react with NO to formONOO•, maintain-
ing VSMC relaxation. Abbreviations: CA, cinnamaldehyde; nNOS, neuronal NOS; ONOO•, peroxynitrite; O2
•, superoxide; sGC, soluble guanylyl
cyclase; KATP, ATP-sensitive K
+ channels, VSMC, vascular smooth muscle cell. Dotted line represents proposed pathway.
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been reported (Grant et al., 2005). Although the nature of the
mechanism of this residual response remains to be deter-
mined, we hypothesize that the mediator involve may be
NO. Stimulation of sensory nerves can also release NO to con-
trol vasoactive responses. Here, we found an increase in NO
formation in cinnamaldehyde-treated ear tissues, as mea-
sured by the Griess assay, and pre-treatment with L-NAME
showed a marked decrease in cinnamaldehyde-induced vaso-
dilatation response. There are no selective eNOS isoform in-
hibitors available; however, a selective nNOS inhibitor
SMTC blocked cinnamaldehyde-induced vasodilatation.
SMTC was used at a dose known to selectively target nNOS
in vivo, with only transient increase in blood pressure in stud-
ies using conscious rats (Gozal et al., 1996). This ﬁnding
builds on our recent discovery of a link between TRPA1 acti-
vation and nNOS-derived NO (Aubdool et al., 2014). Pretreat-
ment with L-NAME or SMTC with the sensory neuropeptide
receptor antagonists abolished cinnamaldehyde-induced va-
sodilatation. Notably, NO has been previously reported to
regulate release of CGRP but not the action of sensory vasodi-
lator CGRP (Holzer and Jocic, 1994; Hughes and Brain, 1994;
Kajekar et al., 1995; Bellamy et al., 2006). This is evident in
studies where L-NAME has no effect in reducing CGRP-
induced vasodilatation in the rabbit (Hughes and Brain,
1994) and rat (Ralevic et al., 1992) skin. Because both the
CGRP receptor antagonist and nNOS inhibitor inhibit the
cinnamaldehyde-induced vasodilatation, this suggests that
both mediators are involved in mediating TRPA1-induced
neurogenic vasodilatation, but possibly sequentially such
that they are both able to inﬂuence the response at different
stages (Figure 6).
It is evident from this study that the sensory neurons play
a major role to elicit neurogenic-dependent vasodilatation
following TRPA1 activation by cinnamaldehyde in the skin.
However, a vascular role of TRPA1 has been suggested. Whilst
it is established that TRPA1 channels are present on the endo-
thelium of cerebral arteries, the TRPA1 channel was not
found in other vascular beds such as coronary, mesenteric or
renal arterial endothelium in rats (Sullivan et al., 2015). It
is presently unknown whether TRPA1 is present in the
vascular beds of the mouse ear, and this requires further in-
vestigation, which is beyond the scope of this study. It has
also been suggested that TRPA1 is present in keratinocytes
(Kwan et al., 2009), but the functional importance of this
in vasodilatation is currently unclear. We hence propose
that cinnamaldehyde acts on functional TRPA1 in the
mouse ear skin to mediate neurogenic vasodilatation.
Hydrogen sulphide (H2S) and nitroxyl (HNO) has recently
been suggested as potential endogenous TRPA1 agonists of
neurogenic vasodilatation (Pozsgai et al., 2012; Eberhardt
et al., 2014; Dux et al., 2016).
CGRP- and substance P-induced vasodilatation involves
the participation of ROS (Starr et al., 2008). We showed that
pretreatment with the powerful antioxidant N-acetylcysteine
signiﬁcantly decreased this response. This is consistent with
previous in vitro ﬁndings whereby N-acetylcysteine blocked
cinnamaldehyde-induced ROS production in human leukae-
mia promyeolocytic cells (Ka et al., 2003). However, there is
evidence that RONS such as peroxynitrite can react vigor-
ously with thiol groups, oxidizing N-acetylcysteine (Szabo
et al., 2007) or possibly cinnamaldehyde, further interfering
with its ability to activate TRPA1. To further conﬁrm any po-
tential role of ROS/RONS in our response, we investigated
other ROS/RONS pathways modulators. Treatment with
apocynin at a dose where it acts as a ROS scavenger rather
than a selective NADPH oxidase (NOX) inhibitor (Heumuller
et al., 2008) reduced cinnamaldehyde-induced vasodilata-
tion, further implying a novel role of RONS in this response.
CGRP- and substance P-induced vasodilatation is
inhibited by SOD and catalase, suggesting an involvement
of superoxide and H2O2 (Starr et al., 2008). Here, whilst treat-
ment with the H2O2 scavenger catalase had no effect on
cinnamaldehyde-induced vasodilatation, pre-treatment with
the SOD mimetic TEMPOL reduced cinnamaldehyde-
induced responses. This ﬁnding supports the partial involve-
ment of SOD in the TRPA1-mediated vascular responses
(Aubdool et al., 2014). Furthermore, a signiﬁcant decrease in
superoxide levels was detected in cinnamaldehyde-treated
ear tissue samples, which can possibly result due to genera-
tion of RONS, peroxynitrite through an interaction between
NO and superoxide. Indeed, co-treatment of L-NAME with
apocynin blocked cinnamaldehyde-induced vasodilatation,
suggesting an important role for NO and ROS in mediating
this vasodilator response.
Notably, we observed a signiﬁcant increase in protein ty-
rosine nitration levels, as assessed by immunoblotting using
a marker for peroxynitrite in cinnamaldehyde-treated tis-
sues. Cinnamaldehyde-induced vasodilatation and associ-
ated increase in peroxynitrite formation was signiﬁcant
reduced in mice pre-treated with the peroxynitrite scavenger
FeTPPS. This provides strong evidence of a role of
peroxynitrite in cinnamaldehyde-induced vasodilatation.
Peroxynitrite is known to exert vasorelaxation on peripheral
blood vessels under physiological conditions (Beckman
et al., 1990; Dowell and Martin, 1997) via stimulation of
cGMP (Casey et al., 2012) and activation of KATP channels
(Villa et al., 1994).
We further examined whether peroxynitrite is formed
upstream or downstream of TRPA1 activation by
cinnamaldehyde and demonstrated that cinnamaldehyde-
induced increase in protein tyrosine nitration was abolished
in TRPA1 KO mice. Collectively, our results suggest that
cinnamaldehyde-induced RONS generation, especially
peroxynitrite, is possibly involved downstream of TRPA1
activation by cinnamaldehyde (Figure 6B). However, once
generated, we cannot exclude the possibility of RONS acting
directly on TRPA1 to mediate vascular effects as TRPA1 can
act as a ROS sensor (Andersson et al., 2008; Eberhardt et al.,
2014; Andersson et al., 2015; Sullivan et al., 2015). Indeed,
peroxynitrite can activate TRPA1 by oxidizing its cysteine res-
idues (Andersson et al., 2015). There is also evidence showing
that NADPH oxidase 2-derived superoxide is converted to
H2O2 and later to OH, leading to peroxidation of membrane
lipids, which activates TRPA1 and causes dilatation in
cerebral arteries (Sullivan et al., 2015). Whilst we show that
H2O2 is not involved here, it is unknown whether
cinnamaldehyde induces lipid peroxidation in our current
study. Thus, it is possible that TRPA1-induced peroxynitrite
formation following cinnamaldehyde treatment can directly
activate TRPA1, leading to a positive modulatory action of
RONS on TRPA1 to mediate vasodilatation in the skin
vasculature.
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Conclusion
In conclusion, our ﬁndings show that cinnamaldehyde can
activate TRPA1 and emphasize the established important
role of CGRP in mediating neurogenic vasodilatation in the
microvasculature. We found that nNOS-derived NO is
important in mediating this response. We provide novel
evidence for the regulatory role of RONS in TRPA1-mediated
neurogenic vasodilatation and demonstrated that
peroxynitrite is generated downstream of TRPA1 activation
by cinnamaldehyde. These results demonstrate the intimate
links between neurogenic vasodilatation and oxidative
mechanisms. Thus, we propose that TRPA1 plays a role in reg-
ulating vascular tone in the periphery and this mechanistic
pathway may help in further understanding the role of
TRPA1 in pathophysiological situations.
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Figure S1 Dose–response curve for cinnamaldehyde
(CA)-induced blood ﬂow responses. Blood ﬂow was measured
in response to topical application of 20 μl of cinnamaldehyde
(1-30%) and vehicle (10% DMSO in ethanol) in the
anaesthetised WT mice ear. Results were recorded over
30 min and analysed as area under the curve (AUC). All errors
indicate SEM. (n = 5). *P < 0.05 vs. vehicle-treated (two-tailed
Student’s t-test).
Figure S2 Effect of 10% cinnamaldehyde (CA)-induced
blood ﬂow responses. Blood ﬂow was measured in response
to topical application of 20 μl of cinnamaldehyde (10%) and
vehicle (10% DMSO in ethanol) in the anaesthetised WT
mice ear. (A) Representative blood ﬂow trace of CA-induced
response in WT mouse. Dotted line represent topical
administration of CA or vehicle. (B) Group mean data for
CA-induced vasodilatation in WT mice for blood ﬂow re-
sponses recorded over 60 min and analysed as area under
the curve (AUC). All errors indicate SEM (n = 4).
Figure S3 Effects of inhibitors on cinnamaldehyde-induced
vasodilatation. Blood ﬂow was measured in response to topi-
cal cinnamaldehyde (10% CA) and vehicle (10% DMSO in
ethanol) in the anaesthetised mouse ear. Results recorded
over 30 min and analysed as area under the curve (AUC). (A)
WTmice were pre-treated with the non-selective cation chan-
nel blocker ruthenium red (3 mg kg-1) or control (saline). (B)
WT mice were pre-treated with the non-selective cyclooxy-
genase inhibitor indomethacin (20 mg kg-1) or control (5%
or 0.05% NaHCO3 in saline). Data shows mean + SEM.
*P < 0.05 vs. vehicle-treated, #P < 0.05 vs. CAtreated ears of
WT mice (2-WAY ANOVA, Bonferroni post hoc test).
Figure S4 Cinnamaldehyde (CA)-induced vasodilatation is
not dependent on iNOS derived nitric oxide. Blood ﬂow was
measured in response to topical application of 20 μl of
cinnamaldehyde (10% CA) and vehicle (10% DMSO in etha-
nol) in the anaesthetised mouse ear. Results were recorded
over 30 min and analysed as area under the curve (AUC).
Group mean data for CA-induced vasodilatation in WT mice
pre-treated with (A) the selective iNOS inhibitor 1400 W
alone (3 mg kg-1, n = 9) or control (saline, n = 9) and (B)
a combination of 1400 W (3 mg kg-1) with CGRP8-37
(400 nmol kg-1) and SR140333 (480 nmol kg-1) or control
(saline, n = 5-7). All errors indicate SEM. *P < 0.05 vs.
vehicle-treated, #P < 0.05 vs. CA-treated ears of WT mice
(2-WAY ANOVA, Bonferroni post hoc test).
Figure S5 Effects of Tetraphenylporphinesulfonate (TPPS)
on cinnamaldehyde (CA)-induced vasodilatation. Blood ﬂow
was measured in response to topical application of 20 μl of
cinnamaldehyde (10% CA) and vehicle (10% DMSO in etha-
nol) in the anaesthetised mouse ear. Results were recorded
over 30 min and analysed as area under the curve (AUC).
Group mean data for CA-induced vasodilatation in WT mice
pre-treated with TPPS (30 mg kg-1, n = 5) or control (saline,
n = 5). All errors indicate SEM. *P < 0.05 vs. vehicle-treated
ears of WT mice (2-WAY ANOVA, Bonferroni post hoc test).
Figure S6 Uncropped immunoblots for Figure 5C-D
displayed in the main ﬁgures. Immunoblots are developed
using Syngene gel doc digital dark room system. A digital im-
age of themembrane is acquired, following which, the immu-
noblot is developed to reveal the probed protein bands (kDa).
(A) Amerged image of the capturedmembrane and developed
nitrotyrosine immunoblot (left panel), and uncropped im-
munoblot for nitrotyrosine for Figure 5C (right panel). (B) A
merged image of the captured membrane and developed β-ac-
tin immunoblot (left panel), and uncropped immunoblot for
β-actin for Figure 5C (right panel) for vehicle and
cinnamaldehyde-treated tissue samples in WT mice pre-
treated with FeTPPS (30 mg kg-1) or control. (C) Amerged im-
age of the captured membrane and developed nitrotyrosine
immunoblot (left panel), and uncropped immunoblot for
nitrotyrosine for Figure 5D (right panel). (D) A merged image
of the captured membrane and developed β-actin immuno-
blot (left panel), and uncropped immunoblot for β-actin for
Figure 5D (right panel) for vehicle and cinnamaldehyde-
treated tissue samples in TRPA1 WT and KO mice. Boxed
areas indicate the cropped regions displayed in Figure 5C-D.
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